Categories
Articles

Featured Items


9/14/2022
The COVID-19 Evidence Reviews website will be discontinuing updates at the end of September 2022. The website will remain available through April 2023. Additional COVID-19 evidence resources can be found on the Resources page.


9/07/2022
The CDC has a COVID-19 County Check tool that allows you to see the COVID-19 community levels for any U.S. county.


8/31/2022
The FDA has authorized updated COVID-19 booster shots against the omicron subvariants. The full statement can be read at the link below.


8/24/2022
The COVID-19 Treatment Guidelines Panel has updated the Anti-SARS-CoV-2 Monoclonal Antibodies section of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. It now includes information on the in vitro susceptibility of the circulating SARS-CoV-2 variants of concern to the available anti-SARS-CoV-2 monoclonal antibodies.


7/28/2022
The CDC updated has added information on the Novavax COVID-19 vaccine with an overview and safety information.


7/14/2022
Check out our new collection for evidence syntheses on Long COVID!


7/07/2022
The Knowledge to Policy (K2P) Center launched the K2P COVID-19 Series Initiative to provide real time evidence and bridge the gap between science, policy, and politics. K2P is a collection of evidence informed documents that aim to inform and provide insights for action to help shape the collective response needed to mitigate the COVID-19 outbreak.


6/08/2022
Harvard T.H. Chan School of Public Health experts have been speaking to a variety of media outlets and writing articles about the pandemic to provide evidence-based context to relevant issues. You can find a selection of articles at the link below.


6/01/2022
The COVID-19 Treatment Guidelines Panel has published a new version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, with updates on MIS-C, antithrombotic therapy, corticosteroids, and special considerations in adults and children with cancer.


5/19/2022
The COVID-19 Treatment Guidelines Panel has revised the Ritonavir-Boosted Nirmatrelvir (Paxlovid) section with a focus on drug-drug interactions.


5/05/2022
The COVID-19 Treatment Guidelines Panel has published a new version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, with updates to dosing guidance, the use of ivermectin as a treatment for COVID-19, and the use of anti-SARS-CoV-2 monoclonal antibodies.


3/03/2022
In response to and EUA issued by the FDA, the COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of bebtelovimab as an additional treatment option for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.


2/24/2022
The World Health Organization maintains a global COVID-19 dashboard with information on cases, mortality, and vaccine doses.


2/17/2022
The CDC updated its guidance for COVID-19 vaccination following receipt of monoclonal antibodies or convalescent plasma; patients who have recently received these treatments no longer need to delay COVID-19 vaccination.


2/11/2022
The February newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


2/02/2022
The COVID-19 Treatment Guidelines Panel (the Panel) has just published a revised version of the “Coronavirus Disease 2019 (COVID-19) Treatment Guidelines” with updated information on infection prevention, monoclonal antibodies, and special considerations for people with HIV.


1/26/2022
The COVID-19 Treatment Guidelines Panel have updated their statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19 to address changes to monoclonal antibody treatment due to the prevalent Omicron variant of concern.


1/19/2022
Every home is the U.S. is eligible to order four free at-home COVID-19 tests through USPS, beginning January 19, 2022.


1/12/2022
The January newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


1/06/2022
The COVID-19 Treatment Guidelines Panel have updated their recommendations on the use of tixagevimab plus cilgavimab as a pre-exposure prophylaxis in certain individuals who, if infected, are at high risk of progressing to severe COVID-19.


12/29/2021
The CDC issued new guidance on the recommended isolation period for people who contract COVID-19, shortening the previous recommendation of 10 days to 5 days (if asymptomatic and wearing a mask for 5 days afterwards).


12/23/2021
The COVID-19 Treatment Guidelines Panel have updated their recommendations, with key updates regarding therapeutic management of hospitalized adults with COVID-19, monoclonal antibodies, convalescent plasma, interferons, colchicine, and fluvoxamine.


12/16/2021
The December newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


12/08/2021
An NIH-funded study to understand the immune responses associated with vaccine-acquired protection against SARS-CoV-2 was recently published in Science. The findings of the study show that antibody levels do demonstrate some correlatation with how well a vaccine works to prevent infection.


12/01/2021
The CDC issued a statement on the emerging Omicron variant of COVID-19, with more information to come as it becomes availalble.


11/24/2021
This articles describes an innovative methodology for the development of a registry constantly updated for the scientific assessment and analysis of the health status of the population with COVID-19 in different clinical settings.


11/17/2021
The CDC has provided guidance for healthcare and public health providers on the use of COVID-19 vaccine boosters.


11/10/2021
The November newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


11/03/2021
An overview of the research on long COVID by CADTH provides awareness of what is known about this condition, emerging research questions, and implications for health care systems.


10/27/2021
The CDC has expanded the eligibility for COVID-19 booster shots, with booster recommendations available for all three COVID-19 vaccines (Moderna, Pfizer, and Johnson & Johnson).


10/20/2021
The COVID-19 Treatment Guidelines Panel have updated their recommendations for the prevention of SARS-CoV-2 infection. The Panel stresses that COVID-19 vaccination remains the most effective way to prevent SARS-CoV-2 infection.


10/13/2021
The NSW COVID-19 Critical Intelligence Unit published a report that examines the evidence on the effectiveness of booster shots for COVID-19 vaccines.


10/06/2021
The COVID-19 Treatment Guidelines Panel released a statement on the EUA of bamlanivimab plus etesevimab as a post-exposure prophylaxis for selected individuals for SARS-CoV-2 infection.


9/29/2021
This study assesses the sensitivity of the Cochrane COVID-19 Study Register and the LOVE COVID-19 platform. The authors concluded that both platforms are sensitive enough to be “a viable screening alternative to searching every individual source”.


9/22/2021
This paper discusses the challenges faced when conducting LSRs in the context of the COVID-19 pandemic, and to provide methodological guidance for others doing similar work. The authors determine that a LSR is a very suitable review type for the pandemic context.


9/15/2021
The COVID19 Evidence Support Team (CEST) aims to produce and update the best available COVID19 evidence to facilitate decision?making in Saskatchewan, Canada. In their first year, CEST has published 135 Evidence Search Reports and 108 rapid reviews on topics related to long term care, public health and prevention, infectious diseases, personal protective equipment, vulnerable populations, and Indigenous health.


9/08/2021
The Health Information Research Unit (HiRU) at McMaster University provides a COVID-19 Evidence Alert service that notifies users to the current best evidence for clincial care of people with COVID-19 infection. Registration for this service is free.


9/01/2021
The COVID-19 Treatment Guidelines Panel has updated their guidance to include new recommendations on when to use dexamethasone in combination with intravenous (IV) sarilumab or oral tofacitinib in certain hospitalized patients with COVID-19. Click the link below to learn more.


8/26/2021
COVID-END and the Coronavirus Variants Rapid Response Network have published a living rapid review on the efficacy and effectiveness of available COVID-19 vaccines for variants of concern.


8/18/2021
The COVID-19 Treatment Guidelines Panel has published a statement on the emergency use authorization of casirivimab plus imdevimab as post-exposure prophylaxis for SARS-CoV-2 infection.


8/11/2021
The August newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


8/04/2021
A recently published study in the journal “Epidemiology and Infection” by Baumeister, Corrin, Abid, et al. found that many evidence syntheses on COVID-19 topics are critically low or low quality, with key domains being left out of the systematic review methodology.


7/28/2021
The CDC publishes Science Briefs on a range of COVID-19 topics that provide a quick overview of the background and research related to a given topic of interest. These Science Briefs are updated as new evidence becomes available.


7/21/2021
Collabovid is a database of published and preprint studies on COVID-19 that uses natural language processing to identify the most relevant information to your query. Additional features include a geographical map of research, topic extraction, and a three-dimensional visualization of COVID-19 research.


7/14/2021
The COVID-19 Treatment Guidelines Panel has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, which includes updates on different treatments for COVID-19 based on the latest evidence.


7/08/2021
The July newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


6/30/2021
The American Society of Health-System Pharmacists maintains a living evidence table for COVID-19 treatments, including antiviral agents, supporting agents, and other drugs and treatments.


6/23/2021
The National COVID-19 Clinical Evidence Taskforce out of Australia maintains a set of living, evidence-based guidelines related to the care of people with COVID-19.


6/16/2021
The COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of anti-SARS-CoV-2 monoclonal antibodies in outpatients with mild to moderate COVID-19 who are at high risk of disease progression. The recommendation now includes the use of Sotrovimab following an EUA issued by the FDA.


6/09/2021
The June newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


6/02/2021
The VA Evidence Synthesis Program has updated its living review on the use of remdesivir in adults with COVID-19. Results from this update align with previous conclusions that remdesivir probably results in little to no difference in mortality or need for ventilation.


5/26/2021
The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate and report on emerging evidence relevant to the COVID-19 pandemic. This group produces Science Briefs on various topics related to COVID-19 and public health.


5/19/2021
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, infection control, and mental health.


5/12/2021
The New South Wales COVID-19 Critical Intelligence Unit provides rapid reviews that outline the available evidence on topics or questions related to the COVID-19 pandemic, with both grey and peer review literature included.


5/05/2021
To make decisions based on the best current evidence, patients, providers, and policy makers often look to systematic reviews and meta-analyses. This guest post by Evan Mayo Wilson, MPA, Dphil, from this past January explores the components that make a systematic review and meta-analysis a reliable source of clinical information.


4/28/2021
The COVID-19 Treatment Guidelines Panel has provided updated guidance on outpatient management of patients with acute COVID-19, including screening, triage, and therapeutic management. It also includes recommendations for managing patients with COVID-19 after they have been discharged from the hospital.


4/14/2021
The COVID-19 Treatment Guidelines Panel has updated its recommendations on the use of anti-SARS-CoV-2 monoclonal antibodies in outpatients with mild to moderate COVID-19 who are at high risk of disease progression. The FDA has approved the use of monoclonal antibodies with an Emergency Use Authorization (EUA).


4/07/2021
The VA ESP has published an update to its rapid review comparing the prevalence of mental health disorders among adults who have been hospitalized for COVID-19 to relevant comparison groups, assesses whether the prevalence of mental health disorders varies by patient and disease characteristics, and ascertains mental health care utilization and resource needs for adults following hospitalization for COVID-19.


3/30/2021
The COVID-END group from McMaster University manage a comprehensive list of COVID-19 resources, from living guidelines to single study sources.


3/25/2021
You can now download the entire COVID-19 Evidence Reviews dataset with the NEW “Download All Reviews” button on the homepage! The file will download as an Excel file.


3/17/2021
The March newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


3/10/2021
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, mental health, and infection control.


3/04/2021
The WHO has published a set of living guidelines on drugs to prevent COVID-19. The guidelines were created with methodological guidance from MAGIC and input from content experts, clinicians, patients, an ethicist and methodologists.


2/24/2021
The NIH COVID-19 Treatment Guidelines Panel have issued a statement on the EUA of bamlanivimab plus etesevimab combination for the treatment of mild to moderate COVID-19.


2/17/2021
A major update has been published to a living systematic review on the use of remdesivir for adults with COVID-19.


2/10/2021
The Society of Critical Care Management (SCCM) has updated their Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). This is the first update since June 2020 and includes nine statements related to ICU patients with severe or critical COVID-19.


2/04/2021
The NIH COVID-19 Treatment Guidelines Panel have updated their statement on the use of tocilizumab and other interleukin-6 inhibitors for the treatment of COVID-19 based on the results of several recent randomized controlled trials, included REMAP-CAP.


1/20/2021
To make decisions based on the best current evidence, patients, providers, and policy makers often look to systematic reviews and meta-analyses. This guest post by Evan Mayo Wilson, MPA, Dphil, explores the components that make a systematic review and meta-analysis a reliable source of clinical information.


1/15/2021
The NIH COVID-19 Treatment Guidelines Panel have been updated to include a statement on the use of ivermectin to treat COVID-19, citing incomplete evidence to support definitive conclusions about its clinical efficacy. Updated guidelines on the use of ivermection should be released in the coming weeks.


1/12/2021
The January newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


12/23/2020
The National Institute for Health and Care Excellence (NICE) has issued new guidance on managing the long-term effects of COVID-19, also known as “long COVID”. One in five people with COVID-19 develop this condition, and the most common symptoms are fatigue, cough, and headache.


12/17/2020
The NIH COVID-19 Treatment Guidelines have been updated to include current information on the clinical presentation of COVID-19, prevention and prophylaxis of SARS-CoV-2 infection, and the use of antithrombotic therapy in COVID-19 patients.


12/09/2020
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, mental health, and infection control.


12/01/2020
The November newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


11/25/2020
The NIH COVID-19 Treatment Guidelines have been updated to include a statement on the emergency use of bamlamivimab for the treatment of COVID-19.


11/18/2020
The University of Michigan manages the COVID-19 Best Evidence Front Door, a direct, single point of access to high quality guideline documents, meta-analyses, and literature syntheses from multiple trusted sources. The Front Door currently contains 359 evidence documents from 61 sources.


11/12/2020
A new Mental Health Collection collection is now available! This curated set of evidence reviews focuses on the mental health impacts of the COVID-19 pandemic on healthcare workers, patients with COVID-19, and the general public.


11/03/2020
The NIH COVID-19 Treatment Guidelines have been updated based on new recommendations and evidence, specifically in sections relating to remdesivir, corticosteroids and vitamin C.


10/23/2020
The NIH COVID-19 Treatment Guidelines have been updated to include a section titled “Influenza and COVID-19”, which provides information on managing these two illnesses concurrently.


10/21/2020
The Center for Evidence Based Medicine at Oxford University has been producing high quality evidence reviews and commentaries on COVID-19 topics. Many of their publications are updated regularly with new evidence.


10/07/2020
The October newsletter is here! Read about our updates on new content, features, and resources. Sign up below to receive our monthly newsletters directly in your inbox!


9/30/2020
The Infectious Diseases Society of America provides up-to-date, evidence-based guidelines on treatment and management, infection prevention, diagnostics, and serology for COVID-19.


9/23/2020
Did you know that in addition to published evidence syntheses, we also catalog evidence synthesis protocols and preprints? You can find these items under Evidence Reviews > Evidence Reviews in Progress.


9/17/2020
The ECRI COVID-19 Resource Center is a great place to search for up-to-date clinical guidelines related to COVID-19.


9/11/2020
The September newsletter is here! Read about our updates on new content, features, and resources, including the new export tool. Sign up below to receive our monthly newsletters directly in your inbox!


9/09/2020
Check out our evidence review Collections under the “Evidence Reviews” tab! These are curated sets of evidence reviews based on key COVID-19 topic areas, including clinical characteristics, candidate therapeutics, diagnostics, and infection control.


9/02/2020
The COVID-19 Treatment Guidelines Panel has released a new statement on the use of convalescent plasma to treat patients with COVID-19, citing the lack of evidence for its effectiveness and recommending against its use as the standard of care.


8/26/2020
Stay up to date on the latest NIH COVID-19 guidelines by subscribing to their notification email. Look for the “Sign up for updates” box on the left side of the NIH COVID-19 Treatment Guidelines website.


8/19/2020
The COVID-19 Evidence Reviews website has implemented some new features! Users can now download abbreviated citation information in a CSV file. We are also launching a monthly newsletter to keep our users up-to-date on key reviews, new features, and opportunities to deliver feedback. Sign up on the homepage!


8/12/2020
The University of Michigan manages the COVID-19 Best Evidence Front Door, a database that assembles meta-analyses, literature syntheses, and clinical guideline documents from multiple highly-reliable sources via a single search.


8/05/2020
The DEPRESSD Project is an international collaborative project to maintain a living systematic review on mental health topics related to COVID-19.


7/29/2020
The NIH released updated guidelines on July 24th regarding the use of remdesivir to treat COVID-19, based on the results of clinical trials and accounting for limited supply.


7/22/2020
The COVID-19 Evidence Network to Support Decision-making (COVID-END) is a comprehensive resource for rapid evidence on the COVID-19 pandemic. The purpose of COVID-END is to encourage cooperation between international evidence synthesis groups and prevent duplication of research effort.


7/15/2020
The VA ESP released a new report that critically appraises a study by Daniel E. Freedberg et al. on famotidine use in hospitalized COVID-19 patients. This type of study review provides additional context for the rapidly growing body of evidence related to COVID-19.


7/09/2020
A new living rapid review from AHRQ was recently published in Annals of Internal Medicine that provides guidance on the use of different types of masks in community and healthcare settings; the review will be updated monthly.


7/07/2020
The VA ESP released an updated rapid response report on corticosteroid therapy for COVID-19 infection to reflect the results from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study.


7/02/2020
The NIH released new guidelines on June 25th regarding the use of dexamethasone for the treatment of patients with COVID-19, based on the results from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study.